Taiwan Journal of Ophthalmology

REVIEW ARTICLE
Year
: 2021  |  Volume : 11  |  Issue : 4  |  Page : 348--351

Gene therapy for retinitis pigmentosa


Niloofar Piri, Jacob D Grodsky, Henry J Kaplan 
 Department of Ophthalmology, School of Medicine, Saint Louis University, St. Louis, MO, USA

Correspondence Address:
Dr. Niloofar Piri
1225 S Grand Blvd, Saint Louis, MO, 63104
USA

Rhodopsin-mediated autosomal dominant retinitis pigmentosa (RP) is the most common cause of RP in North America. There is no proven cure for the disease, and multiple approaches are being studied. Gene therapy is an evolving field in medicine and ophthalmology. In this review, we will go over the basic concept of gene therapy and the different types of gene therapy that are currently being studied to treat this disease.


How to cite this article:
Piri N, Grodsky JD, Kaplan HJ. Gene therapy for retinitis pigmentosa.Taiwan J Ophthalmol 2021;11:348-351


How to cite this URL:
Piri N, Grodsky JD, Kaplan HJ. Gene therapy for retinitis pigmentosa. Taiwan J Ophthalmol [serial online] 2021 [cited 2022 Aug 16 ];11:348-351
Available from: https://www.e-tjo.org/article.asp?issn=2211-5056;year=2021;volume=11;issue=4;spage=348;epage=351;aulast=Piri;type=0